Approaching an age of reason with antiplatelet therapy.
Ajani
Andrew E
AE
Department of Cardiology, Royal Melbourne Hospital, Melbourne, Parkville 3050, VIC, Australia. andrew.ajani@mh.org.au
Lefkovits
Jeffrey
J
D000077144:Clopidogrel; D003327:Coronary Disease / Q000188:drug therapy*; D006801:Humans; D008565:Membrane Proteins / Q000037:antagonists & inhibitors; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D058919:Purinergic P2 Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D015607:Stents / Q000009:adverse effects; D013876:Thiophenes / Q000494:pharmacology / Q000627:therapeutic use*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D008565:Membrane Proteins; C548576:P2RY12 protein, human; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine